Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection
A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection
Sponsor: NEURALIS s.a.
This PHASE2 trial investigates Covid19 and is currently ongoing. NEURALIS s.a. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE2
-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jun 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Sep 2021 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
First recorded
Nov 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NEURALIS s.a.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Biała Podlaska, Poland , Bolesławiec, Poland , Brussels, Belgium , Budapest, Hungary , Gorzewo, Poland , Liège, Belgium , Moscow, Russia , Puławy, Poland , Pécs, Hungary , Saint Petersburg, Russia and 10 more locations